UBC scientists have determined that most of men are found struggling when it comes to comprehending the prostate cancer diagnosis and treatment. Professors John Oliffe and Joan Bottorff are researchers with UBC’s Men’s Health Research Program. While studying men’s literacy or knowledge of prostate cancer, they realized that majority of them are in the dark about what they know regarding this disease. More importantly, they are unaware of what actions to take following diagnosis.
Oliffe proclaimed that in terms of health literacy, there is a long record of people saying men are not up to speed. He added that this includes their understanding when it comes to comprehending prescription medications and dosages, whether they are aware of the stages of a disease and how they utilize the knowledge they have. Health literacy is the capability to access, understand, and employ health-related data to make informed decisions and take care of personal health.
On a similar note, soon, doctors will be able to detect ovarian and breast cancer with the help of an individual’s saliva. Scientists from the Indian Institute of Technology (IIT), Roorkee, recently disclosed that they have formed a novel noninvasive technique to detect ovarian as well as breast cancer through salivary proteins.
Ovarian and breast cancer are said to be two of the worst types of cancer. They are responsible for almost one-third of all cancers that are found in women and one-fifth of all cancer-related fatalities worldwide. The research team has achieved a breakthrough in identifying particular proteins found in the saliva. These proteins work as potential biomarkers pinpointing ovarian and breast cancer metastasis. The research team compared the samples from healthy participants against the samples gathered from stage IV ovarian and breast cancer patients. These samples as well included ovarian cancer patients who had undergone a minimum 3 cycles of chemotherapy. The salivary proteins were examined by mass spectrometry indicative of pathophysiology of ovarian and breast cancers.